Buy Erlonat : Erlotinib 150 Mg Tablets 30’S Online

Description

Description:

Erlonat is a medication used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It contains the active substance erlotinib, which belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Here’s a detailed description:

1. Indications: Erlonat is primarily indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has certain mutations in the epidermal growth factor receptor (EGFR) gene. It is also used in combination with gemcitabine for the treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.
2. Active Substance:
   • Erlotinib: Erlotinib is a reversible inhibitor of the tyrosine kinase activity associated with the epidermal growth factor receptor (EGFR). By blocking EGFR signaling pathways, erlotinib helps inhibit tumor cell growth, proliferation, and survival in cancer cells that overexpress EGFR.
3. Dosage Form: Erlonat is available in tablet form, with each tablet typically containing 150 mg of erlotinib. It is commonly supplied in blister packs containing 30 tablets.
4. Dosage and Administration: The recommended dosage of Erlonat for NSCLC is usually 150 mg taken orally once daily, at least one hour before or two hours after meals. For pancreatic cancer, Erlonat is often used in combination with gemcitabine, with dosing and administration guided by a healthcare provider based on the specific treatment regimen.
5. Mechanism of Action: Erlotinib exerts its therapeutic effects by selectively inhibiting the tyrosine kinase activity associated with the epidermal growth factor receptor (EGFR). By blocking EGFR signaling pathways, erlotinib interferes with tumor cell proliferation, angiogenesis, and metastasis, ultimately leading to inhibition of tumor growth and progression.
6. Benefits:
   • Treatment of NSCLC: Erlonat is effective in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with certain EGFR mutations, offering improved progression-free survival and overall survival outcomes compared to standard chemotherapy.
   • Treatment of Pancreatic Cancer: In combination with gemcitabine, Erlonat provides a treatment option for patients with locally advanced or metastatic pancreatic cancer, offering potential benefits in terms of disease control and symptom management.
7. Side Effects: Common side effects associated with Erlonat may include:
   • Rash or skin irritation
   • Diarrhea
   • Fatigue
   • Nausea and vomiting
   • Loss of appetite
   • Stomatitis (inflammation of the mouth)
   • Elevated liver enzymes
8. Contraindications and Precautions: Erlonat is contraindicated in individuals with known hypersensitivity to erlotinib or any of its components. It should be used with caution in patients with preexisting liver or kidney impairment, interstitial lung disease, or a history of gastrointestinal perforation.
9. Storage: Erlonat tablets should be stored according to the manufacturer’s instructions, typically at room temperature away from light, heat, and moisture. Unused tablets should be kept in their original blister packaging until ready for use.

As with any cancer therapy, the use of Erlonat should be supervised by a qualified healthcare provider experienced in the management of NSCLC and pancreatic cancer. Patients should receive education on proper dosing, potential side effects, and the importance of regular monitoring during treatment to optimize therapeutic outcomes and ensure patient safety. Close communication between patients, caregivers, and healthcare providers is essential for managing treatment-related side effects and addressing any concerns or questions that may arise.